Nippon Glaxo Focus

13 February 1995

- Sir Richard Sykes, chief executive at Glaxo, has reported that taking over full control of Nippon Glaxo "has to be the way to go." The company is 50%-owned by the Konshi family and has not matched the growth in the Japanese market, said Sir Richard (Marketletter January 9). The change in strategy for Glaxo could be expensive as the joint venture has annual sales of L315 million ($491.4 million). This suggests a value for the business of about L1 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight